Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey


Yildiz I., Sen F. , Basaran M. , Ekenel M. , Agaoglu F., Darendeliler E., ...Daha Fazla

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.41, ss.1380-1387, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 41 Konu: 12
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1093/jjco/hyr151
  • Dergi Adı: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.1380-1387

Özet

Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.